Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Angiotensin receptor blockers were associated with worse outcomes in patients with celiac disease ...

In a recent study published in the BMJ, researchers conducted a phase three, multicenter, randomized controlled trial to evaluate the effect of using angiotensin receptor blockers that disrupt the ...

Angiotensin receptor blockers exhibited potential neuroprotective properties for reducing Parkinson disease (PD) risk in patients with newly diagnosed hypertension. A statistically significant ...

CHICAGO — Patients with reduced left ventricular ejection fraction who were discharged after being hospitalized for acute MI and took ACE inhibitors or angiotensin receptor blockers had decreased risk ...

Hypertension control is critical to prevent stroke. With several clinical trials conducted over the last decade, it seems that the use of an angiotensin-modulating antihypertensive agent conveys ...

Scientists have discovered a new generation of angiotensin receptor blockers that may be used to treat coronavirus disease 2019 (COVID-19). In silico docking and molecular dynamics studies have shown ...

Angiotensin II, the principal effector peptide of the renin-angiotensin-aldosterone system (RAAS), has potent vasoconstrictive and other effects that can lead to cardiac and renal complications.

A possible explanation for the severe lung complications being seen in some people diagnosed with COVID-19 is proposed in a new article. James Diaz, MD, MHA, MPH & TM, Dr PH, Professor and Head of ...

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses. Comparative diagnostic accuracy and tumor ...

Type 1 diabetes with CKD is understudied with no advancement of therapy options since the 1990s. The FINE-ONE phase 3 trial addresses a high, unmet need for treatments.

The Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention (MOSES) study was conceived in 1997, when there was little evidence guiding antihypertensive ...